Preferences for chemotherapy in patients with advanced non-small cell lung cancer: descriptive study based on scripted interviews
- 19 September 1998
- Vol. 317 (7161) , 771-775
- https://doi.org/10.1136/bmj.317.7161.771
Abstract
Objective:To determine how patients with lung cancer value the trade off between the survival benefit of chemotherapy and its toxicities. Design:Scripted interviews that included three hypothetical scenarios. Each scenario described the same patient with metastatic non-small cell lung cancer with an expected survival of 4 months without treatment. Subjects were asked to indicate the minimum survival benefit required to accept the side effects of chemotherapy in the first two scenarios (mild toxicity and severe toxicity). In the third scenario, subjects were asked to choose between chemotherapy and supportive care when the benefit of chemotherapy was either to prolong life by 3 months or to palliate symptoms. Subjects:81 patients previously treated with cis-platinum based chemotherapy for advanced non-small cell lung cancer. Main outcome measure:Survival threshold for accepting chemotherapy. Results:The minimum survival threshold for accepting the toxicity of chemotherapy varied widely in patients. Several patients would accept chemotherapy for a survival benefit of 1 week, while others would not choose chemotherapy even for a survival benefit of 24 months. The median survival threshold for accepting chemotherapy was 4.5 months for mild toxicity and 9 months for severe toxicity. When given the choice between supportive care and chemotherapy only 18 (22%) patients chose chemotherapy for a survival benefit of 3 months; 55 (68%) patients chose chemotherapy if it substantially reduced symptoms without prolonging life. Conclusions:Patients' willingness to accept chemotherapy for the treatment of metastatic lung cancer varies widely. Many would not choose chemotherapy for its likely survival benefit of 3 months but would if it improved quality of life. The conflict between these patients' preferences and the care they previously received has several explanations, one being that some patients had not received the treatment they would have chosen had they been fully informed.Keywords
This publication has 14 references indexed in Scilit:
- Trading treatment toxicity for survival in locally advanced non-small cell lung cancer.Journal of Clinical Oncology, 1997
- Chemotherapy vs Supportive Care in Advanced Non-Small-Cell Lung CancerChest, 1994
- Incorporating Patients' Preferences into Medical DecisionsNew England Journal of Medicine, 1994
- Utility Assessment in Cancer PatientsMedical Decision Making, 1994
- Chemotherapy for advanced non-small-cell lung cancer: how much benefit is enough?Journal of Clinical Oncology, 1993
- Polychemotherapy in advanced non small cell lung cancer: a meta-analysisThe Lancet, 1993
- Methods for quality adjustment of life yearsSocial Science & Medicine, 1992
- Attitudes to chemotherapy: comparing views of patients with cancer with those of doctors, nurses, and general public.BMJ, 1990
- Preferences for Health OutcomesMedical Decision Making, 1984
- On the Elicitation of Preferences for Alternative TherapiesNew England Journal of Medicine, 1982